These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37838774)

  • 141. An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
    Wilson NS; Yang B; Yang A; Loeser S; Marsters S; Lawrence D; Li Y; Pitti R; Totpal K; Yee S; Ross S; Vernes JM; Lu Y; Adams C; Offringa R; Kelley B; Hymowitz S; Daniel D; Meng G; Ashkenazi A
    Cancer Cell; 2011 Jan; 19(1):101-13. PubMed ID: 21251615
    [TBL] [Abstract][Full Text] [Related]  

  • 142. T-cell receptor complex is essential for Fas signal transduction.
    Akimzhanov AM; Wang X; Sun J; Boehning D
    Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15105-10. PubMed ID: 20696918
    [TBL] [Abstract][Full Text] [Related]  

  • 143. CD95 promotes tumour growth.
    Chen L; Park SM; Tumanov AV; Hau A; Sawada K; Feig C; Turner JR; Fu YX; Romero IL; Lengyel E; Peter ME
    Nature; 2010 May; 465(7297):492-6. PubMed ID: 20505730
    [TBL] [Abstract][Full Text] [Related]  

  • 144. Expression systems for therapeutic glycoprotein production.
    Durocher Y; Butler M
    Curr Opin Biotechnol; 2009 Dec; 20(6):700-7. PubMed ID: 19889531
    [TBL] [Abstract][Full Text] [Related]  

  • 145. CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling.
    Strauss G; Lindquist JA; Arhel N; Felder E; Karl S; Haas TL; Fulda S; Walczak H; Kirchhoff F; Debatin KM
    J Exp Med; 2009 Jun; 206(6):1379-93. PubMed ID: 19487421
    [TBL] [Abstract][Full Text] [Related]  

  • 146. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
    Ashkenazi A
    Nat Rev Drug Discov; 2008 Dec; 7(12):1001-12. PubMed ID: 18989337
    [TBL] [Abstract][Full Text] [Related]  

  • 147. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease.
    Takeda K; Kojima Y; Ikejima K; Harada K; Yamashina S; Okumura K; Aoyama T; Frese S; Ikeda H; Haynes NM; Cretney E; Yagita H; Sueyoshi N; Sato N; Nakanuma Y; Smyth MJ; Okumura K
    Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10895-900. PubMed ID: 18667695
    [TBL] [Abstract][Full Text] [Related]  

  • 148. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
    Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
    Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
    [TBL] [Abstract][Full Text] [Related]  

  • 149. Lipid rafts and nonrafts mediate tumor necrosis factor related apoptosis-inducing ligand induced apoptotic and nonapoptotic signals in non small cell lung carcinoma cells.
    Song JH; Tse MC; Bellail A; Phuphanich S; Khuri F; Kneteman NM; Hao C
    Cancer Res; 2007 Jul; 67(14):6946-55. PubMed ID: 17638906
    [TBL] [Abstract][Full Text] [Related]  

  • 150. Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib.
    Bi LL; Pan G; Atkinson TP; Zheng L; Dale JK; Makris C; Reddy V; McDonald JM; Siegel RM; Puck JM; Lenardo MJ; Straus SE
    BMC Med Genet; 2007 Jul; 8():41. PubMed ID: 17605793
    [TBL] [Abstract][Full Text] [Related]  

  • 151. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome.
    Del-Rey M; Ruiz-Contreras J; Bosque A; Calleja S; Gomez-Rial J; Roldan E; Morales P; Serrano A; Anel A; Paz-Artal E; Allende LM
    Blood; 2006 Aug; 108(4):1306-12. PubMed ID: 16627752
    [TBL] [Abstract][Full Text] [Related]  

  • 152. Molecular recognition by a binary code.
    Fellouse FA; Li B; Compaan DM; Peden AA; Hymowitz SG; Sidhu SS
    J Mol Biol; 2005 May; 348(5):1153-62. PubMed ID: 15854651
    [TBL] [Abstract][Full Text] [Related]  

  • 153. Autoimmune lymphoproliferative syndrome with somatic Fas mutations.
    Holzelova E; Vonarbourg C; Stolzenberg MC; Arkwright PD; Selz F; Prieur AM; Blanche S; Bartunkova J; Vilmer E; Fischer A; Le Deist F; Rieux-Laucat F
    N Engl J Med; 2004 Sep; 351(14):1409-18. PubMed ID: 15459302
    [TBL] [Abstract][Full Text] [Related]  

  • 154. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death.
    Muppidi JR; Siegel RM
    Nat Immunol; 2004 Feb; 5(2):182-9. PubMed ID: 14745445
    [TBL] [Abstract][Full Text] [Related]  

  • 155. Activation-induced cell death in T cells.
    Green DR; Droin N; Pinkoski M
    Immunol Rev; 2003 Jun; 193():70-81. PubMed ID: 12752672
    [TBL] [Abstract][Full Text] [Related]  

  • 156. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity.
    Cha SS; Sung BJ; Kim YA; Song YL; Kim HJ; Kim S; Lee MS; Oh BH
    J Biol Chem; 2000 Oct; 275(40):31171-7. PubMed ID: 10893238
    [TBL] [Abstract][Full Text] [Related]  

  • 157. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.
    Hymowitz SG; Christinger HW; Fuh G; Ultsch M; O'Connell M; Kelley RF; Ashkenazi A; de Vos AM
    Mol Cell; 1999 Oct; 4(4):563-71. PubMed ID: 10549288
    [TBL] [Abstract][Full Text] [Related]  

  • 158. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.
    Mongkolsapaya J; Grimes JM; Chen N; Xu XN; Stuart DI; Jones EY; Screaton GR
    Nat Struct Biol; 1999 Nov; 6(11):1048-53. PubMed ID: 10542098
    [TBL] [Abstract][Full Text] [Related]  

  • 159. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.
    Pitti RM; Marsters SA; Lawrence DA; Roy M; Kischkel FC; Dowd P; Huang A; Donahue CJ; Sherwood SW; Baldwin DT; Godowski PJ; Wood WI; Gurney AL; Hillan KJ; Cohen RL; Goddard AD; Botstein D; Ashkenazi A
    Nature; 1998 Dec; 396(6712):699-703. PubMed ID: 9872321
    [TBL] [Abstract][Full Text] [Related]  

  • 160. A three-dimensional model of the Fas/APO-1 molecule: cross-reactivity of anti-Fas antibodies explained by structural mimicry of antigenic sites.
    Fadeel B; Lindberg J; Achour A; Chiodi F
    Int Immunol; 1998 Feb; 10(2):131-40. PubMed ID: 9533440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.